InvestorsHub Logo

Whosetosay

03/29/11 10:26 AM

#6616 RE: DonShimoda #6614

Don. when do you expect MRK to produce some data on the Endo trial?

BTH

03/29/11 10:27 AM

#6617 RE: DonShimoda #6614

Don't forget Phase 3 endometrial study to begin (I would think), and initiation of further Phase 2 / 3 combination trials.

biotech_researcher

03/29/11 10:29 AM

#6618 RE: DonShimoda #6614

Don, can we add what Harvey said, "the release of information on new indications for all three of their compounds. Today, we just had the release for the pan-FGFR inhibitor for Pona, which is one. '113 will have one beyond NSCLC, and Rida will have another..

bellweather1

03/29/11 10:31 AM

#6619 RE: DonShimoda #6614

The List Just Really Goes On And On, Doesn't It.

Almost Hard to Believe How Powerful and Positive A Story This Is,

But It's True.

Good To Have Your Input.

Best regards,

bw

yosarian_2

03/29/11 5:42 PM

#6674 RE: DonShimoda #6614

Don, sounds just like my triple, triple. 1,2,3; 4,5,6; 7,8,9; . 10, game over.

As a laugh, Schwab just called me, I am now upgraded to the keys to the executive restroom, red carpet treatment to and from.

Skal, Yo.